Roby Paul Bhattacharyya, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Candidiasis | 2 | 2024 | 365 | 0.900 |
Why?
|
RNA, Bacterial | 3 | 2019 | 391 | 0.880 |
Why?
|
Bacteria | 7 | 2023 | 2102 | 0.870 |
Why?
|
beta-Lactams | 2 | 2021 | 159 | 0.810 |
Why?
|
Candida | 1 | 2022 | 172 | 0.800 |
Why?
|
Drug Resistance, Bacterial | 4 | 2021 | 1032 | 0.710 |
Why?
|
Anti-Bacterial Agents | 8 | 2024 | 7153 | 0.650 |
Why?
|
Nucleic Acid Hybridization | 2 | 2019 | 1374 | 0.640 |
Why?
|
Campylobacter Infections | 1 | 2017 | 32 | 0.620 |
Why?
|
Microbial Sensitivity Tests | 3 | 2021 | 1871 | 0.620 |
Why?
|
Campylobacter jejuni | 1 | 2017 | 26 | 0.620 |
Why?
|
Bacteremia | 3 | 2024 | 962 | 0.600 |
Why?
|
Liver Failure, Acute | 1 | 2017 | 165 | 0.540 |
Why?
|
Hepatitis, Autoimmune | 1 | 2017 | 141 | 0.540 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2019 | 947 | 0.520 |
Why?
|
Viruses | 1 | 2018 | 374 | 0.490 |
Why?
|
Carbapenems | 4 | 2022 | 117 | 0.450 |
Why?
|
Tuberculosis, Splenic | 1 | 2011 | 2 | 0.400 |
Why?
|
Fever of Unknown Origin | 1 | 2011 | 93 | 0.370 |
Why?
|
Communicable Diseases | 1 | 2018 | 878 | 0.350 |
Why?
|
Saccharomyces cerevisiae Proteins | 4 | 2006 | 1884 | 0.290 |
Why?
|
Saccharomyces cerevisiae | 4 | 2022 | 2749 | 0.280 |
Why?
|
Protein Kinases | 3 | 2006 | 1638 | 0.270 |
Why?
|
Pheromones | 1 | 2006 | 98 | 0.260 |
Why?
|
MAP Kinase Signaling System | 3 | 2006 | 1525 | 0.240 |
Why?
|
Mitogen-Activated Protein Kinases | 2 | 2006 | 1284 | 0.240 |
Why?
|
Sepsis | 3 | 2024 | 2589 | 0.230 |
Why?
|
Klebsiella pneumoniae | 2 | 2024 | 246 | 0.220 |
Why?
|
Enterobacter | 1 | 2022 | 46 | 0.220 |
Why?
|
Dyspnea | 1 | 2011 | 1298 | 0.220 |
Why?
|
Klebsiella Infections | 1 | 2024 | 137 | 0.220 |
Why?
|
DNA, Bacterial | 2 | 2018 | 1465 | 0.220 |
Why?
|
Gene Transfer, Horizontal | 1 | 2022 | 145 | 0.200 |
Why?
|
Protein Conformation | 2 | 2006 | 4013 | 0.190 |
Why?
|
Interferon Type I | 1 | 2024 | 542 | 0.180 |
Why?
|
Fungal Proteins | 2 | 2006 | 912 | 0.170 |
Why?
|
Weight Loss | 1 | 2011 | 2604 | 0.170 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2020 | 365 | 0.160 |
Why?
|
Latent Tuberculosis | 1 | 2021 | 225 | 0.160 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 276 | 0.160 |
Why?
|
Mycobacterium tuberculosis | 3 | 2019 | 1825 | 0.160 |
Why?
|
Alanine | 1 | 2020 | 572 | 0.160 |
Why?
|
Virulence | 1 | 2022 | 1328 | 0.150 |
Why?
|
Gene Expression Profiling | 4 | 2023 | 9410 | 0.150 |
Why?
|
Host-Parasite Interactions | 1 | 2019 | 294 | 0.150 |
Why?
|
Mycobacterium | 1 | 2019 | 249 | 0.150 |
Why?
|
Jaundice | 1 | 2017 | 89 | 0.150 |
Why?
|
Evolution, Molecular | 3 | 2021 | 1937 | 0.150 |
Why?
|
Neisseria gonorrhoeae | 1 | 2019 | 238 | 0.140 |
Why?
|
South Africa | 1 | 2022 | 1728 | 0.140 |
Why?
|
Ribonucleases | 1 | 2017 | 287 | 0.140 |
Why?
|
Tularemia | 1 | 2016 | 35 | 0.140 |
Why?
|
Liver Function Tests | 1 | 2017 | 528 | 0.140 |
Why?
|
Ribotyping | 1 | 2015 | 35 | 0.130 |
Why?
|
Gene Library | 2 | 2017 | 1076 | 0.130 |
Why?
|
Protein Folding | 1 | 1999 | 843 | 0.130 |
Why?
|
Pseudomonas Infections | 1 | 2019 | 608 | 0.130 |
Why?
|
Sequence Analysis, RNA | 3 | 2023 | 2011 | 0.130 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2006 | 2915 | 0.130 |
Why?
|
Dengue Virus | 1 | 2017 | 204 | 0.130 |
Why?
|
Phylogeny | 2 | 2019 | 2797 | 0.130 |
Why?
|
Pseudomonas aeruginosa | 2 | 2019 | 1210 | 0.130 |
Why?
|
Skin Ulcer | 1 | 2016 | 118 | 0.130 |
Why?
|
Cross Infection | 1 | 2024 | 1413 | 0.120 |
Why?
|
Lab-On-A-Chip Devices | 2 | 2017 | 428 | 0.120 |
Why?
|
Lymphatic Diseases | 1 | 2016 | 324 | 0.120 |
Why?
|
RNA, Ribosomal | 1 | 2015 | 246 | 0.120 |
Why?
|
Inservice Training | 1 | 2016 | 392 | 0.120 |
Why?
|
Unnecessary Procedures | 1 | 2016 | 431 | 0.110 |
Why?
|
Myocarditis | 1 | 2020 | 770 | 0.110 |
Why?
|
Fatal Outcome | 1 | 2017 | 1849 | 0.110 |
Why?
|
Immunocompromised Host | 1 | 2017 | 847 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3130 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3236 | 0.100 |
Why?
|
Genome, Bacterial | 1 | 2017 | 754 | 0.100 |
Why?
|
DNA, Viral | 1 | 2018 | 2224 | 0.100 |
Why?
|
Cuba | 1 | 2011 | 47 | 0.100 |
Why?
|
Microfluidics | 1 | 2017 | 662 | 0.100 |
Why?
|
Clinical Laboratory Techniques | 1 | 2016 | 740 | 0.100 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 944 | 0.100 |
Why?
|
Staphylococcus aureus | 1 | 2019 | 1449 | 0.090 |
Why?
|
Models, Molecular | 5 | 2006 | 5454 | 0.090 |
Why?
|
Cause of Death | 1 | 2020 | 3571 | 0.090 |
Why?
|
Protein Structure, Secondary | 2 | 2006 | 1245 | 0.090 |
Why?
|
Pilot Projects | 1 | 2022 | 8297 | 0.090 |
Why?
|
RNA | 1 | 2019 | 2747 | 0.080 |
Why?
|
Humans | 26 | 2024 | 742088 | 0.080 |
Why?
|
Survival Analysis | 1 | 2021 | 10248 | 0.080 |
Why?
|
RNA, Viral | 1 | 2017 | 2899 | 0.080 |
Why?
|
Binding Sites | 3 | 2006 | 6115 | 0.080 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1175 | 0.080 |
Why?
|
Phenotype | 3 | 2022 | 16331 | 0.080 |
Why?
|
Signal Transduction | 3 | 2024 | 23387 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1967 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2021 | 2195 | 0.080 |
Why?
|
Radiography, Abdominal | 1 | 2011 | 537 | 0.080 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2536 | 0.080 |
Why?
|
Myocardium | 1 | 2020 | 4775 | 0.070 |
Why?
|
Tuberculosis | 1 | 2019 | 1904 | 0.070 |
Why?
|
Radiography | 1 | 2017 | 7010 | 0.070 |
Why?
|
Delirium | 1 | 2017 | 1608 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2749 | 0.070 |
Why?
|
Genomics | 2 | 2024 | 5692 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 12958 | 0.060 |
Why?
|
Genotype | 1 | 2019 | 12946 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2005 | 647 | 0.060 |
Why?
|
Spleen | 1 | 2011 | 2359 | 0.060 |
Why?
|
RNA, Messenger | 1 | 2019 | 13029 | 0.060 |
Why?
|
Allosteric Regulation | 1 | 2006 | 408 | 0.060 |
Why?
|
Emigrants and Immigrants | 1 | 2011 | 519 | 0.060 |
Why?
|
Crystallography, X-Ray | 2 | 2006 | 2014 | 0.060 |
Why?
|
Protein Structure, Tertiary | 3 | 2006 | 3847 | 0.060 |
Why?
|
Bacterial Proteins | 1 | 2017 | 3843 | 0.060 |
Why?
|
Base Sequence | 1 | 2015 | 12797 | 0.060 |
Why?
|
Eukaryotic Cells | 1 | 2004 | 198 | 0.060 |
Why?
|
Mutation | 3 | 2022 | 29717 | 0.060 |
Why?
|
Amino Acid Motifs | 1 | 2006 | 936 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2021 | 5425 | 0.060 |
Why?
|
Enzyme Activation | 2 | 2006 | 3701 | 0.050 |
Why?
|
CARD Signaling Adaptor Proteins | 1 | 2024 | 156 | 0.050 |
Why?
|
Animals | 8 | 2024 | 168561 | 0.050 |
Why?
|
Nucleotidyltransferases | 1 | 2024 | 220 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 1999 | 9639 | 0.050 |
Why?
|
Proline | 1 | 2003 | 458 | 0.050 |
Why?
|
Protein Engineering | 1 | 2004 | 541 | 0.050 |
Why?
|
Candida albicans | 1 | 2024 | 394 | 0.050 |
Why?
|
Cathepsin L | 1 | 2020 | 75 | 0.050 |
Why?
|
Cytochrome c Group | 1 | 1999 | 128 | 0.040 |
Why?
|
Protein Binding | 3 | 2006 | 9387 | 0.040 |
Why?
|
Transcription, Genetic | 2 | 2020 | 7721 | 0.040 |
Why?
|
Kidney Glomerulus | 1 | 2021 | 697 | 0.040 |
Why?
|
Lung | 1 | 2017 | 9826 | 0.040 |
Why?
|
Immunoglobulin A | 1 | 2022 | 992 | 0.040 |
Why?
|
Peptides | 2 | 2022 | 4392 | 0.040 |
Why?
|
Models, Biological | 2 | 2006 | 9581 | 0.040 |
Why?
|
Viscosity | 1 | 1999 | 328 | 0.040 |
Why?
|
Down-Regulation | 1 | 2006 | 3001 | 0.040 |
Why?
|
Horses | 1 | 1999 | 304 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2020 | 1420 | 0.040 |
Why?
|
Thermodynamics | 1 | 1999 | 594 | 0.040 |
Why?
|
Immunomodulation | 1 | 2021 | 540 | 0.040 |
Why?
|
Dimerization | 1 | 1999 | 893 | 0.040 |
Why?
|
Plasmids | 1 | 2022 | 2305 | 0.040 |
Why?
|
Spectrometry, Fluorescence | 1 | 1999 | 689 | 0.040 |
Why?
|
Soil Microbiology | 1 | 2017 | 87 | 0.040 |
Why?
|
Myeloid Cells | 1 | 2021 | 804 | 0.030 |
Why?
|
Protease Inhibitors | 1 | 2020 | 790 | 0.030 |
Why?
|
Clavulanic Acid | 1 | 2014 | 19 | 0.030 |
Why?
|
Serine Endopeptidases | 1 | 2020 | 1073 | 0.030 |
Why?
|
Phosphorylation | 1 | 2006 | 8436 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2004 | 2906 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 4751 | 0.030 |
Why?
|
Organizational Policy | 1 | 2016 | 427 | 0.030 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2020 | 851 | 0.030 |
Why?
|
Dengue | 1 | 2017 | 256 | 0.030 |
Why?
|
Drug Resistance, Microbial | 1 | 2017 | 860 | 0.030 |
Why?
|
Heart Failure | 1 | 2017 | 10856 | 0.030 |
Why?
|
src Homology Domains | 2 | 2004 | 364 | 0.030 |
Why?
|
Viral Load | 1 | 2021 | 3292 | 0.030 |
Why?
|
beta-Lactamases | 1 | 2014 | 303 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2023 | 2183 | 0.030 |
Why?
|
ROC Curve | 1 | 2020 | 3528 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2016 | 20086 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2020 | 2513 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4929 | 0.030 |
Why?
|
Immunity, Innate | 1 | 2024 | 2956 | 0.030 |
Why?
|
Amino Acid Sequence | 2 | 2005 | 13814 | 0.030 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2020 | 1263 | 0.020 |
Why?
|
Kinetics | 1 | 1999 | 6474 | 0.020 |
Why?
|
Up-Regulation | 1 | 2020 | 4211 | 0.020 |
Why?
|
Medical Order Entry Systems | 1 | 2016 | 544 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2005 | 18112 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4554 | 0.020 |
Why?
|
Environmental Monitoring | 1 | 2017 | 1413 | 0.020 |
Why?
|
Monocytes | 1 | 2020 | 2593 | 0.020 |
Why?
|
Pandemics | 2 | 2020 | 8328 | 0.020 |
Why?
|
Neutrophils | 1 | 2022 | 3711 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2024 | 5310 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2017 | 1389 | 0.020 |
Why?
|
Fever | 1 | 2016 | 1612 | 0.020 |
Why?
|
Structure-Activity Relationship | 2 | 2004 | 3133 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2017 | 3920 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2020 | 3801 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 2978 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10943 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8662 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2004 | 7873 | 0.020 |
Why?
|
Female | 4 | 2020 | 379592 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2020 | 3639 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2005 | 55 | 0.020 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2014 | 910 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12773 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10372 | 0.020 |
Why?
|
Mass Screening | 1 | 2021 | 5238 | 0.020 |
Why?
|
Aged | 1 | 2017 | 162944 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81045 | 0.020 |
Why?
|
Middle Aged | 3 | 2016 | 213127 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2017 | 3585 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6483 | 0.010 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2005 | 473 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 9941 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9305 | 0.010 |
Why?
|
Osmolar Concentration | 1 | 2004 | 683 | 0.010 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2004 | 261 | 0.010 |
Why?
|
Models, Chemical | 1 | 2004 | 626 | 0.010 |
Why?
|
Male | 3 | 2020 | 349538 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 19862 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2005 | 2257 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 24913 | 0.010 |
Why?
|
Prognosis | 1 | 2020 | 29010 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 23320 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 2004 | 1310 | 0.010 |
Why?
|
Prospective Studies | 1 | 2022 | 53187 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 15494 | 0.010 |
Why?
|
Cell Cycle | 1 | 2005 | 2964 | 0.010 |
Why?
|
Cohort Studies | 1 | 2020 | 40450 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2005 | 3020 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2005 | 3444 | 0.010 |
Why?
|
Time Factors | 1 | 2015 | 40054 | 0.010 |
Why?
|
Neoplasms | 1 | 2017 | 21596 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 12071 | 0.000 |
Why?
|